Company Overview - Universal Ibogaine Inc. (UI) is a life sciences company focused on transforming addiction treatment using medicalized ibogaine, specifically targeting opioid use disorder through a planned clinical trial in Canada [4] - The company is also developing a holistic addiction treatment protocol at its Kelburn Recovery Centre, aimed at revolutionizing addiction treatment and improving the lives of affected individuals and families [4] Clinical Trial Announcement - UI intends to file a Clinical Trial Application (CTA) with Health Canada within 90 days to investigate ibogaine as a treatment for opioid use disorder [1] - The company has secured a reliable supply of pharmaceutical-grade ibogaine, produced in compliance with Good Manufacturing Practice (GMP) standards, ensuring quality and safety for the clinical trial [2] Leadership Statement - CEO Nick Karos emphasized the company's commitment to advancing innovative addiction therapies and expressed confidence in conducting rigorous clinical studies focused on patient safety and therapeutic effectiveness [3]

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe, effective, and naturally derived psychedelic therapies for people living with serious mental health challenges. Over the past few months, Psyence BioMed (PBM) has made meaningful progress across several fronts: clinical development, strategic positioning, regulatory compliance, and manufacturing stability. Thes ...

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all microbial safety standards for food-grade consumption, as verified by an accredited third-party laboratory. In 2024, Psyence BioMed acquired an equity stake in PsyLa ...

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all microbial safety standards for food-grade consumption, as verified by an accredited third-party laboratory. In 2024, Psyence BioMed acquired an equity stake in PsyLa ...

Overview of Ibeine Treatment - Ibeine, a powerful psychedelic, is presented as a potentially effective but radical alternative treatment for opioid addiction, capable of erasing years of addiction and withdrawal symptoms in a single session [1] - Despite its potential, ibeine remains illegal in the US due to safety concerns, although it is legally available in countries like Mexico and Brazil under varying regulations [2][4] - The medical subculture surrounding ibeine treatment is described as an uncontrolled experiment, existing largely outside mainstream medicine [3] Current Opioid Addiction Treatment Landscape - The standard treatment for opioid addiction in the US is opioid replacement therapy, which involves substituting illegal opioids with opioid medications to reduce withdrawal symptoms and cravings [5] - Current treatments, while effective in reducing harm, are not very effective at achieving complete opioid abstinence [5] - Medications like buprenorphine and methadone are considered the best legal treatment options for opioid addiction in the US [5] Ibeine Efficacy and Risks - Formal clinical trials of ibeine in the US have not been conducted, and the available evidence comes from small observational studies [6] - A 2017 study indicated that 30% of participants reported never using opioids again after ibeine treatment, while another study reported 75% of patients remained opioid-free for a year [6] - Ibeine treatment carries risks, especially without proper screening and medical supervision, making it inaccessible to most Americans addicted to opioids [2][7]

Regulatory Landscape - Colorado is formally reviewing ibogaine for potential legal availability as a treatment for substance use disorders and mental health conditions [1] - This review could position Colorado as the first to legalize the hallucinogen for treatment purposes [1]

Overview of Ibogaine Treatment - Ibogaine is presented as a radical alternative treatment for opioid addiction, distinct from standard approaches [1] - The treatment is illegal in the US due to potential risks, yet sought after by Americans in other countries [2] - Ibogaine is a psychoactive compound from the Tabernanthe iboga shrub, used traditionally in West African ceremonies [3][4] Efficacy and Research - Observational studies suggest ibogaine can interrupt opioid dependence, but it is not a cure [18] - A 2017 study indicated 30% of participants reported no opioid use after ibogaine treatment, while another reported 75% opioid-free for a year [18] - Formal clinical trials are lacking in the US, but Texas is allocating millions in state funds for ibogaine research [17][21] Treatment Process and Risks - Ibogaine treatment involves medically supervised sessions, including heart monitoring, and can induce intense visions and physical reactions [6][10][11] - The primary risk associated with ibogaine is cardiotoxicity and potential death, necessitating careful screening and medical supervision [19] - Treatment costs range from approximately $5,000 to $15,000, making it inaccessible for many [22] Alternative Treatments and Perspectives - Standard opioid addiction treatment in the US involves opioid replacement therapy, but some find it ineffective [14][15] - Experts emphasize that current legal treatments like buprenorphine and methadone remain the best options in the US [16] - Ibogaine is viewed as a "negative pattern interrupter" that can help individuals overcome heroin addiction rapidly [18]